HealthEquity (NASDAQ:HQY) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

HealthEquity (NASDAQ:HQY) announced its earnings results on Tuesday. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.90 by $0.05, FiscalAI reports. HealthEquity had a return on equity of 12.94% and a net margin of 14.86%.The firm had revenue of $334.59 million for the quarter, compared to the consensus estimate of $332.48 million. HealthEquity’s revenue was up 7.3% compared to the same quarter last year.

HealthEquity Trading Up 0.9%

Shares of NASDAQ:HQY traded up $0.73 during midday trading on Tuesday, reaching $79.40. The company’s stock had a trading volume of 1,262,885 shares, compared to its average volume of 1,033,057. HealthEquity has a fifty-two week low of $72.76 and a fifty-two week high of $116.65. The company has a debt-to-equity ratio of 0.46, a quick ratio of 4.13 and a current ratio of 4.13. The firm has a 50 day moving average price of $81.62 and a two-hundred day moving average price of $90.34. The firm has a market capitalization of $6.78 billion, a price-to-earnings ratio of 36.42, a PEG ratio of 0.97 and a beta of 0.26.

Insider Activity at HealthEquity

In other HealthEquity news, EVP Elimelech Rosner sold 10,959 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $95.45, for a total value of $1,046,036.55. Following the completion of the sale, the executive vice president directly owned 45,742 shares in the company, valued at approximately $4,366,073.90. This trade represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Delano Ladd sold 1,500 shares of HealthEquity stock in a transaction on Friday, December 19th. The shares were sold at an average price of $94.72, for a total transaction of $142,080.00. Following the completion of the sale, the executive vice president directly owned 73,979 shares of the company’s stock, valued at approximately $7,007,290.88. This trade represents a 1.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HQY. Wasatch Advisors LP grew its stake in HealthEquity by 4.5% in the fourth quarter. Wasatch Advisors LP now owns 6,589,646 shares of the company’s stock valued at $603,677,000 after acquiring an additional 281,971 shares during the period. AQR Capital Management LLC lifted its holdings in shares of HealthEquity by 59.3% in the 3rd quarter. AQR Capital Management LLC now owns 1,764,268 shares of the company’s stock worth $167,200,000 after purchasing an additional 656,820 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of HealthEquity by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,581,752 shares of the company’s stock worth $144,911,000 after purchasing an additional 22,744 shares in the last quarter. Morgan Stanley grew its position in HealthEquity by 14.1% in the 4th quarter. Morgan Stanley now owns 1,486,057 shares of the company’s stock valued at $136,138,000 after purchasing an additional 183,645 shares during the period. Finally, Geneva Capital Management LLC grew its position in HealthEquity by 1.9% in the 4th quarter. Geneva Capital Management LLC now owns 1,118,576 shares of the company’s stock valued at $102,473,000 after purchasing an additional 20,969 shares during the period. Institutional investors own 99.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “hold (c+)” rating on shares of HealthEquity in a research note on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $120.00 target price on shares of HealthEquity in a report on Friday, December 5th. Citigroup reissued an “outperform” rating on shares of HealthEquity in a research report on Thursday, December 4th. Jefferies Financial Group set a $108.00 price target on shares of HealthEquity in a research report on Thursday, February 19th. Finally, The Goldman Sachs Group lowered shares of HealthEquity from a “neutral” rating to a “sell” rating and set a $89.00 price objective on the stock. in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, HealthEquity presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.00.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.